triple agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-28. Anything still debated is marked as such rather than presented as settled.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
August 3 – Allan Nascimento, 34, mixed martial artist (UFC). August 18 – Glória Menezes, 91, actress. September 9 – Jackson Nascimento, 102, football player (Athletico Paranaense, Corinthians) and manager (Athletico Paranaense). September 14 – Aracy Amaral, 96, art historian and curator, director of the Pinacoteca do Estado de São Paulo (1975–1979) and the Museum of Contemporary Art, University of São Paulo (1982–1986). September 15 – Amelinha Teles, 81, journalist and political activist. Paulo César Martin, 62, journalist and radio host (Folha de S.Paulo, TV Globo, Conrad Editora). September 22 – Rick Sollo, 59, singer-songwriter (Rick & Renner) and Sertanejo music producer. September 26 – Pedro Antônio Marchetti Fedalto, 100, Roman Catholic prelate, auxiliary bishop (1966–1970) and archbishop (1970–2004) of Curitiba.
The respiratory tract has a branching structure, and is also known as the respiratory tree. In the embryo this structure is developed in the process of branching morphogenesis, and is generated by the repeated splitting of the tip of the branch. In the development of the lungs (as in some other organs) the epithelium forms branching tubes. The lung has a left-right symmetry and each bud known as a bronchial bud grows out as a tubular epithelium that becomes a bronchus. Each bronchus branches into bronchioles. The branching is a result of the tip of each tube bifurcating. The branching process forms the bronchi, bronchioles, and ultimately the alveoli. The four genes mostly associated with branching morphogenesis in the lung are the intercellular signalling protein – sonic hedgehog (SHH), fibroblast growth factors FGF10 and FGFR2b, and bone morphogenetic protein BMP4. FGF10 is seen to have the most prominent role. FGF10 is a paracrine signalling molecule needed for epithelial branching, and SHH inhibits FGF10. The development of the alveoli is influenced by a different mechanism whereby continued bifurcation is stopped and the distal tips become dilated to form the alveoli. At the end of the fourth week, the lung bud divides into two, the right and left primary bronchial buds on each side of the trachea. During the fifth week, the right bud branches into three secondary bronchial buds and the left branches into two secondary bronchial buds. These give rise to the lobes of the lungs, three on the right and two on the left.
Daly, M.M.; Mirsky, A.E. (January 1955). "Histones With High Lysine Content". Journal of General Physiology. 38 (3): 405–413. doi:10.1085/jgp.38.3.405. PMC 2147486. PMID 13221780. Allfrey, V.G.; Daly, M.M.; Mirsky, A.E. (January 20, 1955). "Some Observations on Protein Metabolism in Chromosomes of Non-Dividing Cells" (PDF). Journal of General Physiology. 38 (3): 415–424. doi:10.1085/jgp.38.3.415. PMC 2147482. PMID 13221781. Daly, M.M.; Allfrey, V.G.; Mirsky, A.E. (November 20, 1955). "Synthesis of Protein in the Pancreas. III. Uptake of Glycine-N15 by the Trypsinogen and Chymotrypsinogen of Mouse Pancreas" (PDF). Journal of General Physiology. 39 (2): 207–210. doi:10.1085/jgp.39.2.207. PMC 2147525. PMID 13271721. Deming, Q.B.; Mosbach, E.H.; Bevans, M.; Daly, M.M.; Abell, L.L.; Martin, E.; Brun, L.M.; Halpern, E.; Kaplan, R. (April 1, 1958). "Blood Pressure, Cholesterol Content of Serum and Tissues and Atherogenesis in the Rat" (PDF). The Journal of Experimental Medicine. 107 (4): 581–598. doi:10.1084/jem.107.4.581. PMC 2136835. PMID 13513919. Daly, Marie M.; Gupride, E. Gambetta (February 1, 1959). "The Respiration and Cytochrome Oxidase Activity of Rat Aorta in Experimental Hypertension" (PDF). Journal of Experimental Medicine. 109 (2): 187–195. doi:10.1084/jem.109.2.187. PMC 2136939. PMID 13620848. Adel, Harold; Daly, Marie M.; Deming, Quentin B.; Brun, Lili; Raeff, Victoria (1962). "Effect of Hypertension on Cholesterol Synthesis in Rats" (PDF).
Sources: en.wikipedia.org
A diagnosis of myocardial infarction is created by integrating the history of the presenting illness and physical examination with electrocardiogram findings and cardiac markers (blood tests for heart muscle cell damage). A coronary angiogram allows visualization of narrowings or obstructions on the heart vessels, and therapeutic measures can follow immediately. At autopsy, a pathologist can diagnose a myocardial infarction based on anatomopathological findings. A chest radiograph and routine blood tests may indicate complications or precipitating causes and are often performed upon arrival to an emergency department. New regional wall motion abnormalities on an echocardiogram are also suggestive of a myocardial infarction. Echo may be performed in equivocal cases by the on-call cardiologist. In stable patients whose symptoms have resolved by the time of evaluation, Technetium (99mTc) sestamibi (i.e. a "MIBI scan"), thallium-201 chloride or Rubidium-82 Chloride can be used in nuclear medicine to visualize areas of reduced blood flow in conjunction with physiologic or pharmacologic stress. Thallium may also be used to determine viability of tissue, distinguishing whether non-functional myocardium is actually dead or merely in a state of hibernation or of being stunned.
== Controversies == Al-Fawzan has attracted criticism for a number of public statements and religious opinions. In 2003, he was quoted as saying that "slavery is a part of Islam" and that Muslims who deny this are ignorant and not scholars, comments that drew criticism for contradicting some contemporary interpretations of Islamic law. He has also described public demonstrations as haram, characterizing them as practices of non-Muslims that can lead to division and violence. In 2010, he called for a boycott against Adil al-Kalbani, who had stated that music was not haram (forbidden in Islam). The campaign was a fiasco, as the mosque was overcrowded during Adil al-Kalbani's next sermon. In 2011, opposing the Saudi Ministry of Justice's proposal to set a minimum age for girls' marriage, he reportedly issued a legal opinion authorizing fathers to marry off their daughters "even if they are still in the cradle". In 2014, Saleh al-Fawzan denied reports that he issued a fatwa banning open buffets, clarifying on his website that he had only commented that food of unspecified quantity should not be sold without specification. His statement addressed restaurants where customers pay a fixed price for unspecified portions. In 2015, he was quoted as saying that “Muslims must set aside games and frivolity and take up God’s work. They must not waste their time following games and frivolity, especially not during the blessed month of Ramadan. This is true for Muslims in general, and the younger generation in particular...
=== Nests, colonies, and supercolonies === The typical ant species has a colony occupying a single nest, housing one or more queens, where the brood is raised. There are however more than 150 species of ants in 49 genera that are known to have colonies consisting of multiple spatially separated nests. These polydomous (as opposed to monodomous) colonies have food and workers moving between the nests. Membership to a colony is identified by the response of worker ants which identify whether another individual belongs to their own colony or not. A signature cocktail of body surface chemicals (also known as cuticular hydrocarbons or CHCs) forms the so-called colony odor which other members can recognize. Some ant species appear to be less discriminating; in the Argentine ant Linepithema humile, workers carried from a colony anywhere in the southern US and Mexico are acceptable within other colonies in the same region. Similarly, workers from colonies established in Europe are accepted by any other colonies within Europe, but not by the colonies in the Americas. The interpretation of these observations has been debated and some have been termed these large populations as supercolonies while others have termed the populations as unicolonial.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.